Created in 2015 (United States), RAPIVAB own 4 sister brands and 2214 competing brands. RAPIVAB is owned by BioCryst Pharmaceuticals, listed on the stock exchange of New York RAPIVAB belongs to the Biotechnology business sector.

RAPIVAB is a brand of BioCryst Pharmaceuticals (BCRX) Share price

Share price and profitability of the share BioCryst Pharmaceuticals (RAPIVAB)

Buy BioCryst Pharmaceuticals share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Investment simulator :

Amount invested USD 5.15

Portfolio valuation
BioCryst Pharmaceuticals (RAPIVAB) over 5 years* USD 3.26

Stock market history BioCryst Pharmaceuticals (RAPIVAB)

Desirable brands that generate Pricing Power and therefore stock market performance

Only companies with a strong brand or unique know-how benefit from this ability to set their prices without impacting demand and thus preserve their margins.

Read more